Iantrek Secures $42M Series C Financing to Advance Novel Uveoscleral Outflow Therapy for Glaucoma

IantrekAnnounced the completion of a $42 million Series C financing round. This round of financing was led byU.S. Venture Partners (USVP) led the investment,aMoon Fund, Visionary Ventures, Sectoral Asset Management, and other follow-up investors. The proceeds of this financing will be used to support the world's first uveoscleral pathway surgical solution.AlloFlo UveoCommercial launch in the United States and expansion of the product pipeline system.

Investor Evaluation

"This round of financing reflects the market's firm confidence in Iantrek’s disruptive glaucoma interventional therapy. The platform redefines treatment possibilities through operational simplicity, precision, and enhanced efficacy."

---Casey Tansey  USVP General Partner

"Iantrek's cutting-edge solutions not only provide significant clinical value but also bring new minimally invasive treatment options for glaucoma patients. We look forward to...Adam Szaronos"And the entire team worked together to provide a new generation of glaucoma treatment solutions for thousands of patients in need."

---Todd Sone  aMoon Fund General Partner

Executive Evaluation

"Our mission is to address the significant unmet needs in the field of glaucoma treatment. This financing marks a crucial step toward our goal. In the United States, more than 2.5 million eyes have experienced a decline in efficacy after undergoing minimally invasive glaucoma surgery (MIGS) targeting the trabecular meshwork pathway.AlloFlo Uveo"It achieves intervention in another natural drainage system of the eye—the uveoscleral pathway, which is akin to enabling a thoracic surgeon to enhance the function of the second lung."

---Adam Szaronos  CEO of Iantrek

Glaucoma, as a chronic blinding disease, causes irreversible damage to the optic nerve. Clinical management typically involves reducing intraocular pressure by increasing aqueous humor drainage or decreasing aqueous humor production. Healthy eyes have two independent aqueous outflow pathways: the trabecular meshwork pathway and the uveoscleral pathway. Existing MIGS devices focus only on the trabecular meshwork pathway, while Iantrek's BIOS platform has pioneered a minimally invasive breakthrough in the uveoscleral pathway—an area that has long relied on medication, with no surgical enhancement solutions available to date.

This YearIantrekInAnnounced at the American Academy of Ophthalmology Annual MeetingAlloFlo UveoClinical research data. Studies show that using AlloFlo Uveo for bioenhanced ciliary body ablation demonstrates long-term safety and effectiveness. Two-year follow-up data indicates: an average 34% reduction in intraocular pressure, a more than 60% decrease in the use of pressure-lowering medications, with no serious product-related adverse events reported.

Expert Evaluation

"The approximately 3,000 surgeries completed through early clinical programs indicate that surgeons have a clear demand for uveoscleral pathway intervention. Iantrek's bio-interventional therapy is currently the only surgical solution targeting this major drainage pathway, offering the highest therapeutic index in the field of glaucoma treatment."

--- Sean Ianchulev  New York Eye and Ear of Mount Sinai

Iantrek Product Line

Iantrek's product portfolio includes three next-generation bio-interventional and micro-interventional solutions: AlloFlo Uveo, AlloSert Uveo, and C.Rex. These aim to enhance surgical precision and improve access to the eye’s natural outflow pathways. AlloFlo Uveo is the first allograft specifically tailored for ophthalmic applications, enabling durable implantation and biological integration. The company has completed the first-in-human trial of its next-generation bio-interventional products, with commercial launch anticipated by 2026.

Iantrek Products

• Cyclopen(HighPrecision Interventional Ciliary Body Separation: Opening the Uveoscleral Outflow Pathway

CycloPen adopts an ergonomic design and can implant structural reinforcement materials through a cannula to achieve controlled, interventional, and lasting cyclophotocoagulation.

• Instrument System Designed for High-Precision Uveoscleral Intervention

• Used for the formation of controlled ciliary body separation

• Cyclodialysis with Controllable Cannula Implantation and Structural Material Reinforcement

• AlloFlo（NaturalNo ImplantsIantrek's Enhanced Solution via the Domestic Route）

AlloFlo is a bio-interventional solution specifically designed to achieve high-precision endogenous structural reinforcement.AlloFloCan be used to enhance the uveoscleral outflow pathway established by ciliary body separation, sclerostomy, overfiltering trabecular flap, optic disc depression, and other inner scleral structures.

• The World's First Class of Bio-intervention Solutions

• Biocompatible and bioadaptive with surrounding tissues

• Minimal mechanical fibrosis-promoting mismatch with native tissue

• High Porosity and Water Permeability

• C-REX（Breakthrough the Limitations of Traditional Resection Techniques）

C-Rex has revolutionized goniotomy by achieving a circumferential trabeculotomy of up to 360 degrees.

• 180-360 Degree Circumferential Trabeculotomy

• Specifically designed to maximize the treatment of diseased trabecular meshwork

• Adopting Superelastic Memory-Type Nickel-Titanium Alloy Tip Technology

Iantrek

IantrekIs an innovative medical device company,Dedicated to developing bio-interventional and micro-interventional ophthalmic surgical products.